Home Clinical Evidence
Masport® has been evaluated in multiple clinical studies demonstrating its safety and effectiveness for various indications.
A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines
Masport® is as safe and effective as Dysport® for glabellar lines, with comparable efficacy and duration up to 180 days.
DOI: 10.1007/s00266-023-03766-5
The following studies have been published in peer-reviewed medical journals:
Title: Comparison of Two Botulinum Neurotoxin Type A Preparations (Masport and Dysport) for Upper Face Rhytides: A Randomized Clinical Trial
Journal: Aesth Plast Surg, 2025
Title: The Effects of Botulinum Toxin Type A (Masport) on Reducing Sialorrhea in Children with Cerebral Palsy
Journal: Int J Pediatr, Vol.11, N.12, Serial No.120, Dec. 2023
Title: Effectiveness of Local Botulinum Toxin Injection for Perianal Pain after Hemorrhoidectomy
Journal: Middle East J Dig Dis, Vol. 14, No. 3, July 2022
Title: Efficacy of Intracavernosal Injections of 50-Unit Versus 100-Unit Doses of AbobotulinumtoxinA (Masport®) in Vasculogenic Erectile Dysfunction with Phosphodiesterase Type 5 Inhibitors Resistant
Journal: Nephro-Urol Mon. 2022 February; 14(1): e119131
Masport® demonstrates comparable efficacy to established botulinum toxin products in clinical studies.
Well-tolerated with a safety profile consistent with other botulinum toxin type A products.
Efficacy duration up to 180 days demonstrated in glabellar lines treatment studies.
For detailed clinical data, study protocols, or additional research information, please contact our medical affairs team.